Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

887
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
887
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

595
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
595
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

803
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
803
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

392
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
392
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.0K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy.

Endoscopy·2017
Same author

The role of dietary supplements in inflammatory bowel disease: a systematic review.

European journal of gastroenterology & hepatology·2016
Same author

Gallstone mimicry: a rare cause of abdominal pain.

Gut·2016
Same author

Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy.

Endoscopy·2016
Same author

Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?

Gut·2011
Same author

Helicobacter pylori and NSAIDs--the end of the debate?

Lancet (London, England)·2002

Related Experiment Video

Updated: Jan 6, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

707

Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo.

Mark I Hamilton1, Judy Sercombe, Roy E Pounder

  • 1Centre for Gastroenterology, Royal Free and University College Medical School, London, UK.

Digestive Diseases and Sciences
|February 12, 2002
PubMed
Summary

Ranitidine (75 mg) significantly reduced daytime intragastric acidity more than cimetidine (200 mg). Ranitidine

More Related Videos

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.6K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K

Related Experiment Videos

Last Updated: Jan 6, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

707
Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.6K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Intragastric acidity plays a crucial role in digestion and disease.
  • Understanding the duration of action of acid-suppressing medications is vital for effective treatment.

Purpose of the Study:

  • To compare the duration of action of ranitidine (75 mg) and cimetidine (200 mg) on intragastric acidity in healthy subjects.
  • To evaluate the efficacy of single oral doses of these H2-receptor antagonists.

Main Methods:

  • Healthy subjects received single oral doses of ranitidine (75 mg), cimetidine (200 mg), or placebo.
  • Intragastric acidity was measured over a 20-hour period post-dosing.
  • Statistical analysis was performed to compare treatment effects against placebo and between ranitidine and cimetidine.

Main Results:

  • Ranitidine (75 mg) demonstrated a significantly greater reduction in daytime intragastric acidity (59% decrease) compared to cimetidine (200 mg) (35% decrease) (P < 0.001).
  • Ranitidine also showed a greater inhibitory effect on nighttime intragastric acidity (18% decrease) than cimetidine (2% decrease) (P = 0.043).
  • The acid-inhibitory effect of ranitidine was detectable for up to 15 hours, while cimetidine's effect diminished significantly after 10 hours.

Conclusions:

  • Single oral doses of ranitidine (75 mg) provide a longer and more potent inhibition of intragastric acidity compared to cimetidine (200 mg) in healthy individuals.
  • Ranitidine offers a more sustained acid suppression, extending beyond 10 hours, unlike cimetidine.
  • These findings support ranitidine's efficacy in managing conditions requiring prolonged acid control.